Clinical trial

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

NCT02834013

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Study at a glance

Registry-backed

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov
StatusACTIVE_NOT_RECRUITING
Study typeINTERVENTIONAL
Start date2017-01-30
PhasePHASE2
Advertisement

Conditions

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.